Effortless Affielisa® Human Homocysteine-responsive Endoplasmic Reticulum-resident Ubiquitin-like Domain Member 1 Protein Elisa [ Herpud1] With A 50% Price Cut [VNHnxdG9]

Highly Sensitive HERPUD1 Protein ELISA Kit

The AffiELISA® Human Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein ELISA [HERPUD1] is a cutting-edge assay designed to detect and quantify Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1) levels in various biological samples. This kit offers a reliable and convenient method for researchers studying the role of HERPUD1 in cellular processes and its association with various diseases.

Key Features and Specifications

The AffiELISA® Human HERPUD1 ELISA kit is equipped with a highly sensitive detection system that ensures accurate and reproducible results. It features a proprietary capture antibody that specifically binds to HERPUD1, allowing for a high specificity and sensitivity. The kit includes all necessary reagents, including standards, controls, and buffers, to streamline the experimental process. Here are some of the key features and specifications of this kit:

• High Sensitivity: Detects HERPUD1 levels as low as 0.78 pg/ml
• Specificity: High specificity for HERPUD1 with minimal cross-reactivity to other proteins
• Simple and Rapid Protocol: Results can be obtained in just 90 minutes
• High Reproducibility: Ensures consistent and reliable results across multiple experiments

Practical Applications

The AffiELISA® Human HERPUD1 ELISA kit is an invaluable tool for researchers in various fields, including neurobiology, immunology, and oncology. Its applications include:

• Studying HERPUD1 Function: Investigate the role of HERPUD1 in cellular processes and its potential as a therapeutic target
• Diagnosis and Monitoring: Aid in the diagnosis and monitoring of diseases associated with HERPUD1, such as neurological disorders and autoimmune diseases
• Drug Development: Facilitate the development of novel drugs targeting HERPUD1 for the treatment of various diseases